G. Caramori (Ferrara, Italy), A. Barczyk (Katowice, Poland), G. Joos (Ghent, Belgium), C. Wiegman (London, United Kingdom)
Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, administered to healthy male subjects in a phase I study
R. Wilson, A. Cahn, A. Deans, I. McSherry, C. Rambaran, A. Sousa, D. Wilbraham (Stevenage, London, United Kingdom)
|   |
Inhibition of inflammatory gene expression by dexamethasone partly depends on the phosphatase, MKP-1 (DUSP1)
S. Shah, E. King, R. Newton (Calgary, Canada)
| |
Cytokine-induced glucocorticoid resistance: Effect on GILZ expression and reversal by formoterol
C. Rider, J. Chivers, A. Miller-Larsson, M. Giembycz, R. Newton (Calgary, Canada; Mölndal, Sweden)
| |
Potential effect of the extract of zataria multiflora and its consituent carvacrol on lung inflammation of sensitized guinea pigs
M. H. Boskabady, A. Tabatabaee, S. Jalali (Mashhad, Islamic Republic Of Iran)
| |
Involvement of the JAK-STAT3 pathway in a lipopolysaccharide-induced rat model of airway inflammation
E. Calama, A. Domenech, C. Carreño, J. De Alba, N. Prats, M. Miralpeix, I. Ramis (Sant Feliu de LLobregat, Spain)
| |
Surfactant-enforced treatment of pseudomonas-induced pneumonia
A. Birkun (Simferopol, Ukraine)
| |
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma
M. Fitzgerald, M. Whitmarsh, J. Prosser, A. Banyard, P. Lockey (Slough, Harlow, Manchester, United Kingdom)
| |
Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers
O. Esposito, F. Mariotti, D. Acerbi, A. Compagnoni, M. A. Nandeuil (Parma, Italy)
| |
Effects of rosemary and platanus extracts on asthmatic subjects resistant to traditional treatments
M. Mirsadraei, A. Tavakoli, S. Ghaffari (Mashhad, Islamic Republic Of Iran)
| |
Zizyphus spina-christi for the management of adult asthma
M. Rajabi, S. Garusi, H. R. Moezzi, Z. Nasir-Baghban (Tehran, Islamic Republic Of Iran)
| |
Experimental airways hyperreactivity and modulation of glutamatergic and nitrergic signalling
M. Antosová, A. Strapková (Martin, Slovakia)
| |
Bioactivity-guided isolation of bronchodilator fraction from clitoria ternatea roots
D. Taur, R. Patil, R. Patil (Malegaon BK, Baramati, District- Pune, Kharadi, Pune, India)
| |
Can blood investigations be utilised to predict treatment response to omalizumab?
C. Gouder, L. West, S. Montefort (B'Kara, Malta)
| |
A randomised placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers
S. Faruqi, C. Wright, A. Morice (Cottingham, United Kingdom)
| |
A combination of thyme and primula dry extracts possesses antitussive activity and inhibits leukotriene formation
J. Seibel, C. Pergola, O. Werz, K. Wosikowski, J. Haunschild (Neumarkt, Jena, Germany)
| |
Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study
E. Ashry, Y. Gad, M. Yosry, A. Osama, A. Abdelwareth (Assuit, Egypt)
| |
Safety and efficacy of 7% hypertonic saline in patients with bronchiectasis
C. Hodgekiss, J. Slough, T. Capstick, D. Peckham, I. Clifton (Leeds, United Kingdom)
| |
Inhaled mannitol for non-cystic fibrosis bronchiectasis - results of a 12 month, multi-centre, double-blind, controlled study
D. Bilton, G. Tino, A. Barker, D. Chambers, A. De Soyza, L. Dupont, C. O'Dochartaigh, E. van Haren, L. Otero Vidal, T. Welte, H. Fox, J. Wu, B. Charlton (London, Newcastle-upon-Tyne, United Kingdom; Philadelphia, Portland, United States Of America; Brisbane, Sydney, Australia; Leuven, Belgium; Auckland, New Zealand; Heerlen, Netherlands; Partido de Vicente Lopez, Argentina; Hannover, Germany)
| |
Chemically modified mRNA as a novel treatment for cystic fibrosis
A. J. Mahiny, R. Handgretinger, D. Hartl, M. S. D. Kormann (Tuebingen, Germany)
| |
ADEPT, airway disease endotyping for personalized treatment: Interim analysis of asthma patients
M. Loza, I. Strambu, M. Laviolette, D. Singh, J. M. Fitzgerald, S. Kelsen, A. Eich, A. Ludwig-Sengpiel, G. Chupp, C. Porsbjerg, P. Berger, R. Leigh, J. Kline, M. Dransfield, W. Calhoun, A. Hussaini, P. Chanez, V. S. Susulic, P. E. Silkoff, F. Baribaud (Spring House, Philadelphia, New Haven, Iowa City, Birmingham, Galveston, Baltimore, United States Of America; Bucharest, Romania; Québec, Manchester, United Kingdom; Vancouver, Calgary, Canada; Frankfurt, Lübeck, Germany; Copenhagen, Denmark; Bordeaux, Marseille, France)
| |